Understand the source comparison
AOD-9604 Compare to Other Research Peptides: Comparison Table
AOD-9604 Beta-3 adrenergic agonism Beta-3 adrenergic receptors (adipocytes) Direct lipolysis via cAMP → PKA → HSL activation Adipose tissue only. No BBB penetration None. Does not activate GH receptors Best choice for appetite-independent lipolysis studies req
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AOD-9604
- Beta-3 adrenergic agonism
- Beta-3 adrenergic receptors (adipocytes)
- Direct lipolysis via cAMP → PKA → HSL activation
- Adipose tissue only. No BBB penetration
- None. Does not activate GH receptors
- Best choice for appetite-independent lipolysis studies requiring metabolic isolation without hormonal confounders
- Semaglutide
- GLP-1 receptor agonism
- GLP-1 receptors (hypothalamus, pancreas, GI tract)
- Appetite suppression, delayed gastric emptying
- Central + peripheral. Crosses BBB
- None. Insulin sensitisation without GH pathway involvement
- Ideal for appetite modulation research; introduces too many systemic variables for isolated lipolysis studies
- Tirzepatide
- Dual GLP-1/GIP agonism
- GLP-1 + GIP receptors
- Appetite suppression + enhanced insulin sensitivity + energy partitioning shift
- Central + peripheral
- None. Incretin pathway only
- Superior weight loss efficacy but mechanistically complex; difficult to isolate individual pathway contributions
- Ipamorelin
- GH secretagogue
- Ghrelin receptors (pituitary GHS-R1a)
- Pulsatile GH release → IGF-1 elevation → downstream lipolysis + anabolism
- Systemic via GH/IGF-1 axis
- High. Elevates IGF-1 by 40–60% at therapeutic doses
- Useful for anabolic + lipolytic combination studies; confounds pure fat loss research due to muscle protein synthesis effects
- CJC-1295
- Long-acting GH secretagogue
- Ghrelin receptors (pituitary)
- Sustained GH elevation over 6–8 days
- Very high. Prolonged IGF-1 elevation
- Best for sustained anabolic research; excessive hormonal cascade for short-term metabolic studies
- BPC-157
- Gastric peptide analogue
- Multiple (VEGF, growth factor pathways, nitric oxide signalling)
- Angiogenesis, tissue repair, anti-inflammatory signalling
- Broad. Documented BBB penetration
- Indirect via growth factor upregulation
- Excellent for injury recovery models; unsuitable for metabolic research requiring variable isolation